Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Anika Therapeutics (ANIK) EBITDA Margin: 2010-2025

Historic EBITDA Margin for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to -9.03%.

  • Anika Therapeutics' EBITDA Margin rose 8976.00% to -9.03% in Q3 2025 from the same period last year, while for Sep 2025 it was -28.61%, marking a year-over-year increase of 8325.00%. This contributed to the annual value of -47.72% for FY2024, which is 2030.00% up from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' EBITDA Margin is -9.03%, which was up 2.77% from -9.29% recorded in Q2 2025.
  • Anika Therapeutics' EBITDA Margin's 5-year high stood at 2,151.74% during Q4 2023, with a 5-year trough of -98.80% in Q3 2024.
  • For the 3-year period, Anika Therapeutics' EBITDA Margin averaged around 170.60%, with its median value being -16.02% (2025).
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 201,346bps in 2023, then crashed by 222,673bps in 2024.
  • Anika Therapeutics' EBITDA Margin (Quarterly) stood at -17.29% in 2021, then skyrocketed by 15,557bps to 138.28% in 2022, then skyrocketed by 201,346bps to 2,151.74% in 2023, then tumbled by 222,673bps to -74.99% in 2024, then skyrocketed by 8,976bps to -9.03% in 2025.
  • Its EBITDA Margin stands at -9.03% for Q3 2025, versus -9.29% for Q2 2025 and -16.02% for Q1 2025.